Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEL-CTD in previously untreated multiple myeloma
NCT00438841Phase 2Unknown
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2006
- Primary completion
- Dec 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Fred Hutchinson Cancer Center. Status: unknown.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00438841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00438841.